Effects of non-invasive brain stimulation for degenerative cerebellar ataxia: a protocol for a systematic review and meta-analysis

Akiyoshi Matsugi,1 Hiroyuki Ohtsuka,2 Kyota Bando,3 Yuki Kondo,3 Yutaka Kikuchi4

ABSTRACT

Introduction To date, the medical and rehabilitation needs of people with degenerative cerebellar ataxia (DCA) are not fully met because no curative treatment has yet been established. Movement disorders such as cerebellar ataxia and balance and gait disturbance are common symptoms of DCA. Recently, non-invasive brain stimulation (NIBS) techniques, including repetitive transcranial magnetic stimulation and transcranial electrical stimulation, have been reported as possible intervention methods to improve cerebellar ataxia. However, evidence of the effects of NIBS on cerebellar ataxia, gait ability, and activity of daily living is insufficient. This study will aim to systematically evaluate the clinical effects of NIBS on patients with DCA.

Methods and analysis We will conduct a preregistered systematic review and meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. We will include randomised controlled trials to assess the effects of NIBS on patients with DCA. The primary clinical outcome will be cerebellar ataxia, as measured by the Scale for Assessment and Rating of Ataxia and the International Cooperative Ataxia Rating Scale. The secondary outcomes will include gait speed, functional ambulatory capacity and functional independence measure, as well as any other reported outcomes that the reviewer considers important. The following databases will be searched: PubMed, Cochrane Central Register of Controlled Trials, CINAHL and PEDro. We will assess the strength of the evidence included in the studies and estimate the effects of NIBS.

Ethics and dissemination Because of the nature of systematic reviews, no ethical issues are anticipated. This systematic review will provide evidence on the effects of NIBS in patients with DCA. The findings of this review are expected to contribute to clinical decision-making towards selecting NIBS techniques for treatment and generating new clinical questions to be addressed.

PROSPERO registration number CRD42023379192.

INTRODUCTION

Degenerative cerebellar ataxia (DCA) is a group of inherited neurodegenerative disorders that are characterised by progressive cerebellar ataxia. Representative diseases include autosomal dominant spinocerebellar ataxia (ADSCA), spinocerebellar ataxia (SCA), Friedreich’s ataxia (FA), multiple system atrophy with cerebellar ataxia (MSA-C), sporadic adult-onset ataxia of unknown aetiology (SAOA) and autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). The pathological hallmark of almost all types of DCA is the loss of neurons such as Purkinje cells in the cerebellum, which leads to its atrophy. In addition, degeneration of other neuronal populations in the cerebellum, brainstem and spinal cord contributes to the wide range of clinical manifestations of DCA. These diseases lack adequate treatment, and the associated movement disorders are progressive and have a significant impact on the patients’ daily living activities and quality of life. These diseases are rare, and while treatment methods are being developed, they remain insufficient to meet patients’ medical needs.

Some pharmacological and non-pharmacological treatments have been recommended in previous systematic research based on clinical studies. One of the treatments for movement disorders includes non-invasive brain stimulation (NIBS) techniques, such as repetitive transcranial magnetic stimulation and transcranial electrical stimulation.
and disabilities is neurorehabilitation, including high-intensity physical and occupational therapy. Conventional interventions, such as weighted orthoses and balance training, are applied by clinicians. Additionally, non-invasive brain stimulation (NIBS), such as repetitive transcranial magnetic stimulation (rTMS) and transcranial electrical stimulation (tES), is also used for neuromodulation.

Single-pulse TMS can induce action potentials in the focal cortical site of the brain, resulting in temporal effects on motor and sensory function. Moreover, rTMS can induce more long-term changes in neural activity and function than single-pulse stimulation. rTMS has thus been studied as a potential treatment for mental disorders, cognitive dysfunction, pain, movement disorders after stroke, symptoms of Parkinson’s disease, multiple sclerosis and cerebellar ataxia. These studies have indicated that rTMS can be performed to obtain long-term desirable effects on the symptoms of cerebellar and other neural diseases and in a safe manner in these patients.

Recent systematic reviews and meta-analyses have investigated the effects of rTMS on cerebellar ataxia, including patients with DCA and patients who had a stroke. One review has reported that rTMS improves scores on the International Cooperative Ataxia Rating Scale (ICARS), the Scale for the Assessment and Rating of Ataxia (SARA), the Berg Balance Scale and in Timed Up and Go tests. These findings indicate that rTMS has the potential to improve cerebellar ataxia, balance and gait dysfunction. However, the effect of rTMS may be affected by other conditions, including stroke and degenerative diseases. About 80% of cases with cerebellar ataxia after cerebellar stroke reach an independent level of activity of daily living within 3 months after onset. DCA, on the other hand, causes a gradual loss of Purkinje cells in the cerebellar cortex and functional compensations in the deep cerebellar nuclei and cerebral cortex, gradually resulting in significant dynamic changes in the cerebro-cerebellar system over time. Because the pathophysiology of stroke and DCA differ considerably, there may be too much heterogeneity to unify the effects of rTMS. In addition, the quality and heterogeneity of the studies should be considered. One systematic review on the effect of rTMS on DCA included seven randomised controlled trials (RCTs), but a recent report that aimed to improve cerebellar ataxia with a novel stimulus parameter of rTMS was not included. The reason this RCT was excluded is that the prior systematic review limited the disease to cerebellar ataxia with a novel stimulus parameter of rTMS.

The aforementioned previous systematic reviews and meta-analyses about tES and rTMS were appropriately conducted, but they considered each intervention independently. Furthermore, several important, more recent RCTs were published after analysis. In the current study, tES and rTMS are treated as a single NIBS approach same as previous systematic review and meta-analysis,32 and their joint effect size will be assessed at the present time. This comprehensive analysis may contribute to estimate whether brain stimulation itself improves DCA symptoms. Moreover, we will create tES and rTMS subgroups and compare their effect sizes on the outcomes. In clinical practice, only one tES or rTMS technique can be employed at a time, and clinicians must have a rationale for choosing one technique over the other. Therefore, an indirect comparison of their effect sizes and new recommendations for their selection may be useful for patients with DCA and clinicians.

Regarding the safety and tolerability of rTMS and tES in patients with DCA, no severe harmful side effects and only minimal unfavourable events were recorded. In contrast, additional investigations are necessary to ascertain the most suitable NIBS parameters and evaluate their influence on the clinical outcomes of patients with DCA. More specifically, the polarity of tES, the frequency (high or low) of rTMS and the site of stimulation (cerebellum itself or other sites) are also important. The effects of these stimulus parameters on efficacy should also be examined in this systematic review and meta-analysis.

This study will aim to systematically review the available data on the use of NIBS, including rTMS or tES, as a therapeutic intervention for cerebellar ataxia in patients with DCA. This review will address the following research questions: (1) What is the impact of rTMS and tES on the degree of ataxia? (2) Which rTMS and tES stimulation parameters have been used in previous studies, and how
these have impacted the results; and (3) What must be evaluated in future research.

METHODS AND ANALYSIS
This systematic review will be conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement (see online supplemental file ‘PRISMA-P-checklist’). This protocol has been registered in the International Prospective Register of Systematic Reviews (PROSPERO) database.

Patient and public involvement
None.

Participants
We will include studies involving patients with DCA and exclude studies involving individuals with ataxia other than DCA. DCA encompasses a large number of diagnoses, which typically are ADSCA, SCA, FA, MSA-C, SAOA, and ARSACS. SCA is most typically of the SCA1, 2, 3, 6 and 31 subtypes, among others. These diseases mainly arise with a later onset, being even rarer in patients less than 18 years old. Therefore, the age range covered in this systematic review is restricted to above 18 years old. Pharmacological treatment and rehabilitation therapies are standard treatments and are usually preferred over NIBS. Since most of the cases treated with NIBS also receive these two treatments concurrently, they will be included in both the intervention and comparator groups.

Interventions
NIBS, namely rTMS and tES, will be included as interventions for cerebellar ataxia. Transcranial alternating current stimulation, tDCS, and transcranial random noise electrical stimulation will be included as tES types.

Comparators
No intervention and active control interventions, such as sham stimulation or treatment, will be included as comparators. However, physical therapy, occupational therapy and pharmacotherapy will not be included solely as control treatments for NIBS. These therapies will be included in both the intervention and comparator groups.

Outcomes of interest
The primary clinical outcome will be cerebellar ataxia, as measured by SARA and ICARS scores. The use of these scales is recommended for assessment of cerebellar ataxia as a clinician-reported outcome measure. The secondary outcomes will include gait speed, functional ambulatory capacity (FAC) and functional independence measure (FIM), as well as any other reported outcomes that the reviewer considers important. The weighted mean difference and the mean and SD will be used for continuous data. The standard mean difference will be used to summarise multiple measures of the same outcome items.

Study design
The inclusion criteria for the studies are single-blind or double-blind RCTs published in English with full-text availability. Only peer-reviewed articles will be included. The exclusion criteria are review articles, conference abstracts and letters to the editor.

Information sources and search strategy
The following databases will be searched: PubMed, Cochrane Central Register of Controlled Trials, CINAHL and PEDro. The searches will be restricted to English and human participants. Abstract and conference proceedings will not be included. The main search words are set to be the following: ‘cerebellum’, ‘spinocerebellar degeneration’, ‘ataxia’, ‘transcranial magnetic stimulation’, ‘transcranial electrical stimulation’ and ‘clinical trial’. A draft of the search strategy for the above databases is provided in the supplementary file (online supplemental appendix 1). The review will encompass all eligible studies published from database inception until the present time.

Data extraction (selection and coding)
The search will be performed by one independent reviewer using the databases, and four other reviewers will confirm the initial list of papers. The search terms will consist of a combination of medical subject heading (MeSH) terms and free text search terms in the database, based on author consensus. Rayyan and EndNote V.20 will be used to manage the studies across databases.

For each study, a pair of two independent reviewers randomly assigned from a group of five reviewers (AM, HO, KB, YKo and YKi) will screen the study title and abstract for determining whether the study meets the inclusion criteria. Studies that cannot be judged only by the title and abstract will be evaluated by referring to the full text. During the initial evaluation, the identity of the other reviewer is blinded to the pair. If the decisions of the two reviewers are inconsistent, a third reviewer will participate in the discussion and make the final decision. At this stage, the pair is informed about the identity of the reviewer assessing the applicable study.

Data extraction will be performed by two independent reviewers to obtain precise information on the study design and methodology, participant demographics and baseline characteristics, sample size and effect measurements. Discrepancies will be resolved by the participation of a third reviewer in the discussion. We will contact study authors for any missing data, if needed. If the authors do not respond to our request or refuse to provide data, we will analyse only the available data. Data extraction will be performed using Microsoft Excel spreadsheets.

Risk of bias in individual studies
The risk of bias will be assessed using the Cochrane risk of bias tool (RoB 2.0). Two of the five independent reviewers will critically evaluate the included studies. The
evaluation items include the following: (1) bias arising from the randomisation process; (2) bias due to deviation from the intended intervention; (3) bias due to missing outcome data; (4) bias in the measurement of outcomes; (5) bias in the selection of reported results. For each item, we will evaluate each study as having a low, uncertain or high risk of bias. Any discrepancies will be discussed and resolved by a third reviewer, if necessary.

Data synthesis
If more than two randomised (or quasi-randomised) controlled trials report the same outcome, such as SARA and ICARS scores, FAC gait speed or FIM, a meta-analysis will be performed. RevMan V.5.4 software will be used for the meta-analysis and to calculate the weighted mean difference, and the mean and SD will be used for continuous data. The standard mean difference will be used to summarise multiple measures of the same outcome items. Random effect models will be used to obtain pooled estimates, and the results will be described using forest plots. The F test will be used to evaluate heterogeneity; if the F value exceeds 50%, heterogeneity will be judged to be high, and a subgroup analysis will be performed. A summary table of the published results will be prepared. If a quantitative synthesis is not appropriate, we will provide a summary table about NIBS montage, stimulation parameters, patient diagnosis, effect size of the intervention on outcomes and main findings in individual studies.

Analysis of subgroups or subsets
First, to examine the effects of NIBS, one meta-analysis will be conducted without separating tES and rTMS. Next, a subgroup analysis will be performed based on the type of intervention such as polarity of tES, frequency and location of rTMS. Furthermore, a subgroup analysis will be performed based on participant characteristics, such as sex and diagnosis (such as DCA or multiple system atrophy), and use of control (no intervention or active control) if there was more than one arm in each trial. Z-tests will be used to elucidate the differences in NIBS (tES and rTMS).38

Assessment of strength of evidence
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework will be employed to assess the overall quality of evidence across all outcomes. This will involve evaluating the individual risk of bias, meta-bias, precision, consistency, directness and magnitude of effect. These indicators are used to determine the level of certainty associated with the estimated effect, which is classified as ‘very low’, ‘low’, ‘high’ or ‘very high’.

ETHICS AND DISSEMINATION
There will be no requirement for ethical approval because this systematic review will not include original data from human beings. The results will be disseminated through peer-reviewed publication.

DISCUSSION
The present review will aim to summarise the available evidence on the effects of rTMS and tES in the treatment of DCA. The review will encompass all eligible studies published from inception until the present time and will assess the quality of the studies and analyse outcome data. One strength of this study is the expansion of the target population to patients with DCA, as in the past the study population was limited to patients with SCA and MSA. Another strength is the calculation and comparison of the effect sizes of tES and rTMS in the same systematic review and meta-analysis study, as they have been difficult to compare in the past. Furthermore, with the publication of several new RCTs since the latest systematic review, a better estimation of the effect size of NIBS is expected. The findings generated by this systematic review and meta-analysis may contribute to the clinical decision-making regarding the use of NIBS and the choice of NIBS technique for treating an individual patient with DCA.

There are potential concerns in the interpretation of the results in the current systematic review and meta-analysis. One concern is that stimulation methods for tES and rTMS have evolved over time. For example, attention should be paid to probing placement and stimulation duration in electrical stimulation, and coil geometry and pulse intervals in magnetic stimulation. It is important to note that these technological developments may lead to differences in the size of NIBS effects on the outcomes. We plan to report a detailed summary of the intervention methods for each study and discuss their impact on outcomes. Furthermore, we should note that the effects of rTMS and tES may differ due to differences in the areas that can be stimulated. Moreover, the price of the equipment and the cost of the application of rTMS and tES may differ. Additionally, while patients can receive tES at home, this is more difficult with rTMS treatment. Therefore, recommendations should consider the effectiveness as well as the accessibility of the devices. Moreover, the anticipated limitations to the study include the scarcity of high-quality trials and an insufficient homogeneity of data to allow quantitative analysis. We should also pay attention to the heterogeneity and diverse baseline severity of the included diseases. These concerns may have to be addressed in future clinical studies, and a future research agenda will be proposed accordingly.

The treatment of DCA aims to reduce symptoms associated with ataxia, including gait disturbance. The use of NIBS for treating these symptoms is still in the research stage and has not yet been implemented in clinical practice. To establish optimal clinical practices, evidence regarding stimulation parameters is critical. These parameters include not only the stimulation site of the brain but also factors such as polarity and intensity in tES, as well as frequency in rTMS. Taken together, we believe...
that the results of our systematic review and meta-analysis study will provide valuable insights that will help patients with DCA and healthcare professionals make decisions regarding the selection of NIBS as a treatment approach. If our systematic review and meta-analysis do not provide sufficient insights regarding clinical use, we will propose specific clinical questions regarding research on the impact of these parameters on treatment outcomes.

Twitter Akiyoshi Matsugi @matsu__aki, Hiroyuki Ohtsuka @HiroyukiOhtsuka, Kyoto Bando @kyota_bando and Yutaka Kikuchi @stiidous_kick

Acknowledgements We appreciate Ms. Tomoko Morimasa and Ms. Asako Baraki, librarians at Showa University, for their support in developing the search strategies. We would like to thank Editage (www.editage.jp) for the English language editing.

Contributors AM, HO, KB, YKo and YKi conceptualised the study. AM and HO designed the protocol. AM and HO defined the search items, data extraction process and statistical analysis. AM drafted the initial manuscript. All authors have appraised the whole methodology, and revised and approved the final manuscript.

Funding This study was supported by the Japan Society for the Promotion of Science (USPS) KAKENHI (grant number, 20K11238) and the Institute of Health Sciences at Shijonawate Gakuen University (grant number, IHS2301).

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is acknowledged and the conditions stated in the license are followed. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Akiyoshi Matsugi http://orcid.org/0000-0002-3244-0874

REFERENCES


